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Activated zinc transporter ZIP7 as an indicator of
anti-hormone resistance in breast cancer
Silvia Ziliotto, a Julia M. W. Gee,a Ian O. Ellis,b Andrew R. Green,b Pauline Finlay,a
Anna Gobbatoa and Kathryn M. Taylor *a
ZIP7, a member of the ZIP family of zinc importers, resides on the endoplasmic reticulum membrane
and transports zinc from intracellular stores to the cytoplasm after activation by CK2 phosphorylation on
two serine residues (S275 and S276). ZIP7 is known to be required for the growth of anti-hormone
resistant breast cancer models, especially those with acquired tamoxifen resistance developed from
MCF-7. Using our new pS275S276ZIP7 antibody which only recognises activated ZIP7 (pZIP7), we have
demonstrated that the hyperactivation of ZIP7 is prevalent in tamoxifen-resistant breast cancer cells.
This evidence suggests that pZIP7 might have potential as a biomarker of acquired resistance to such
anti-hormones in breast cancer, a current unmet clinical need. In this regard, we have also developed a
new immunohistochemical assay for pZIP7 which allowed pZIP7 to be tested on a small clinical series of
breast cancer tissues confirming its prevalence in such tumours and relationship to a variety of
clinicopathological parameters and biomarkers previously associated with endocrine resistant phenotypes,
notably increased activated MAPK signalling, expression of ErbB2, CD71 and the proto-oncogene c-Fos, as
well as with increased tumour grade.
Significance to metallomics
Our work elucidates the role of zinc in breast cancer and in particular its relevance to endocrine resistance, a currently unmet need in the therapy of oestrogen-
positive breast cancer. While our previous studies have identified a rise in intracellular zinc as a characteristic typical of anti-hormone resistance, here we have
expanded this research and identified the mechanism that leads to this event. This work increases our understanding of the role of zinc transporters in the
development of diseases such as cancer, an aspect of zinc biology which still remains elusive.
A Introduction
Zinc is one of the most important trace elements in the human
body, acting as a cofactor for more than 300 enzymes.1 It is
essential for several bodily functions including RNA transcription,
DNA synthesis, cell division and activation of growth factors
promoting signalling pathways.2 Recently, zinc deficiency and
uncontrolled cellular zinc levels have been implicated in a
number of important diseases,3 such as growth retardation,4,5
immunodeficiency,6 neurodegeneration,7 diabetes and cancer,3,8,9
making it a potential target for therapy. Furthermore, zinc excess is
also associated with increased migration and exaggerated cell
growth making zinc dysregulation an important driver of
cancer.9 In particular, there is clinical evidence of increased
zinc levels in breast cancer tissues when compared to normal
breast tissue,10 suggesting the importance of maintaining
proper zinc homeostasis in tissues. The first zinc transporter
to be related to breast cancer was ZIP6 (also called SLC39A6 and
LIV-1) which is an oestrogen-regulated gene11 associated with
cancer spread to the lymph nodes12 and a feature of luminal A
breast cancer.13
Zinc cannot traverse cell membranes and therefore relies on
two families of zinc transporters, the ZnT family (termed
SLC30A) of zinc exporters and the ZIP family (termed SLC39A)
of zinc importers14 to control cellular zinc homeostasis. ZIP7,
an SLC39A family member, is situated on the endoplasmic
reticulum membrane15 and is essential for the release of zinc
from intracellular stores. This ZIP7-mediated zinc release
requires phosphorylation by protein kinase CK2 on two serine
residues (S275 and S276) on the long intracellular loop of ZIP7
between TM III and TM IV.16 We have now developed a unique
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monoclonal antibody which binds ZIP7 only when phosphorylated
on these two serine residues17 and have demonstrated that the
mobilisation of zinc induced by the activation of ZIP7 is involved in
regulating growth factor signalling of many pathways known to be
responsible for aggressive cancer growth. This eﬀect is directly
due to the ability of released zinc to inhibit multiple tyrosine
phosphatases, especially PTP1B.18 These data confirm previous
observations showing ZIP7 abundance in tumours and additionally
its position as one of the top 10% genes overexpressed inmany poor
prognostic cancer states.9
Breast cancer is the second most commonly diagnosed cancer
worldwide and the most common among women,19 making it a
serious worldwide issue that still needs to be tackled. Breast
cancer can be broadly classified according to the expression of
three main proteins: ER (oestrogen receptor), HER2 (human
epidermal growth factor receptor 2) and PR (progesterone
receptor).20 The most common type of breast cancer is oestrogen
receptor positive breast cancer (ER+), which can be targeted with
endocrine therapy such as aromatase inhibitors (AIs), SERMs
(selective estrogen receptor modulators) or pure oestrogen receptor
antagonists (SERD) that aim to reduce or entirely suppress,
respectively, the action of the protein.21 According to NICE
guidelines, standard treatment for breast cancer in postmeno-
pausal disease includes oestrogen deprivation with the use of an
aromatase inhibitor, or tamoxifen if AIs are not tolerated.22 The
anti-oestrogen tamoxifen (a SERM) is used as a first-line treat-
ment in premenopausal women, while the further antioestrogen
Faslodexs (a pure antagonist)21 can be used in later stage
disease and leads to the degradation of the oestrogen receptor.23,24
Recently, tamoxifen was also found to be a useful chemoprevention
agent for women at high risk of breast cancer,25 and although the
risks associated with its prolonged use were uncertain, more recent
studies have demonstrated that prolonging tamoxifen therapy up to
10 years or more instead of the usual 5 years treatment is beneficial
and can reduce both mortality and recurrence.26
Unfortunately, some patients treated with endocrine agents,
including anti-oestrogens, develop resistance27 resulting in disease
relapse and cancer recurrence during treatment,28 generating a
requirement for new targets to allow additional novel therapies to
control this more aggressive state. With this aim, we have pre-
viously developed unique anti-hormone resistant breast cancer
models, both to tamoxifen29 and Faslodexs,30 that aim to mimic
the clinical development of acquired resistance and that can help
in the discovery of new potential targets. Interestingly, our tamoxifen-
resistant MCF-7 derived breast cancer model (TamR) has both a
higher level of available zinc8 and an increased gene expression of
zinc transporter ZIP7.31 Removal of ZIP7 from TamR cells confirmed
its role in activating epidermal growth factor receptor (EGFR) and
insulin-like growth factor receptor (IGF-1R),8 both of which are
known to drive the growth of these TamR cells.32
Here we have extended these previous investigations to
examine whether monitoring the phosphorylation of ZIP7
provides a better indication of changes in zinc signalling pathway
activation in the anti-hormone resistant breast cancer models.
We demonstrated that while our tamoxifen-resistant cells have
increased total ZIP7 protein expression, there is a larger increase
in activated ZIP7, suggesting utilisation of zinc signalling path-
ways. We have confirmed this by detecting concurrent activation of
AKT, also known as protein kinase B which is a serine-threonine
kinase with a well-established role in cancer progression and cell
survival.33 AKT is known to be activated by ZIP7-mediated zinc
release17 which is especially elevated in the tamoxifen-resistant
cells. Furthermore, we have observed that pZIP7 is present in all
tamoxifen-resistant cells compared to only a small percentage of
MCF-7 cells, suggesting ZIP7 activation is key to driving their
anti-hormone resistant growth. We compared these results to
Faslodexs-resistant cells and also examined how they alter over
a more prolonged antihormone exposure time frame to more
fully-reflect clinical resistance. We have also developed an
immunostaining test able to detect pZIP7 in clinical samples
and demonstrated activity of ZIP7 in most breast cancer samples
comprising a small clinical series, with interesting clinicopatho-
logical and biomarker correlations suggesting ZIP7 prevalence in
endocrine resistant tumours. We thus propose that pZIP7 is a
potential indicator of anti-hormone resistance, especially tamoxifen
resistance, which with further study may prove to have biomarker
value for cancer patients treated with anti-hormones.
B Materials and methods
Cell culture and materials
Antihormone responsive MCF-7 cells (human breast adeno-
carcinoma cells), a gift from AstraZeneca (Macclesfield, UK)
and derived anti-hormone resistant cell lines were cultured for
experimentation in phenol-red free RPMI 1640 (Roswell Park
Memorial Institute), 5% charcoal stripped steroid-depleted
fetal calf serum, 200 mM L-glutamine and antibiotics (10 IU
per ml penicillin, 10 mg ml1 streptomycin and 2.5 mg ml1
amphotericin B). The development of the tamoxifen resistant
(TamR)29 and Faslodexs resistant (FasR)30 cell lines has been
previously described (representing resistance developing over
8–10 months). Longer term resistant cell lines were also used
that were developed after a more prolonged exposure (3 years)
of these models to tamoxifen (TamRL) or Faslodexs (FasRL)
respectively.34 Tissue culture media and constituents were
obtained from Life Technologies Europe Ltd (Paisley, UK) and
plasticware from Nunc (Roskile, Denmark). For Western blot or
Immunofluorescence 1–5  105 cells were seeded into 60 mm
or 22  22 mm  0.17 mm thick glass coverslips respectively.
Cells were kept at 37 1C in a 5% CO2 atmosphere.
Western blot
Samples for Western blot were prepared as previously described.17
Primary antibodies were diluted 1 :1000 for anti pZIP7 (MABS1262,
Merck Millipore, USA), total ZIP7 (19429-1-AP, ProteinTecht, USA),
total AKT (#9272, Cell Signaling, USA), pSer473AKT (#9271, Cell
Signaling, USA), total MAPK (#9102, Cell Signaling, USA) and
phospho-MAPK (#9101, Cell Signaling, USA) and 1 : 10 000 for
b-actin or GAPDH (A3854, G9295, Sigma Aldrich, USA). Quanti-
fication of Western blot results was performed by normalisation
to b-actin or GAPDH values and using Alpha DigiDoc software
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4.10 or ImageJ for Mac OS. Some gels were cut horizontally to
enable multiple probing (Fig. 3A–B) thus making the same
GAPDH band appropriate for both sets of results.
Immunofluorescence
Cells were fixed with 3.7% formaldehyde (Sigma Aldrich) and
processed as previously described.15 Cells were probed for
1 hour with primary antibody (anti-pZIP7 1/100, MABS1262,
Merck Millipore, USA) followed by goat anti-mouse Alexa Fluor
594 secondary antibody at 1/1000 dilution (Molecular Probes,
Invitrogen, UK) for 30 minutes. Coverslips were mounted on
microscope slides with Vectorshield mounting medium with
DAPI (Vector Laboratories, USA) and sealed with nail varnish.
Cells were visualised on a Leica RPE automatic microscope using a
63 oil immersion lens. Pictures were acquired and processed
using Openlab software for Macintosh operating system.
Immunohistochemistry
All pellets of the cell models or breast cancer tissue samples
used for the immunohistochemical assays had been formalin-
fixed, embedded in paraﬃn, sectioned and mounted onto
charged slides. The breast cancer series comprised n = 93
primary breast cancer samples who had presented for surgery
at Nottingham City Hospital, with full ethical approval for
immunohistochemical studies (Nottingham Research Ethics
Committee REC2 C2020313). The sections were then washed
in xylene and diﬀerent concentrations of ethanol (from 100% to
70%) through to water in order to rehydrate the sample. After
trying diﬀerent antigen retrieval conditions, the optimal con-
dition for pZIP7 staining was ascertained to be pressure-cook
microwaving at 950 W in pH 8 EDTA buﬀer for 2 minutes. The
assay used the mouse monoclonal pZIP7 antibody (MABS1262,
Merck Millipore, USA) optimised to a 1/8000 dilution for the
cell pellets and 1/800 dilution for breast cancer sections. The
samples were first washed with PBS/Tween 0.02% and then
covered with 0.18% hydrogen peroxidase to block endogenous
peroxidases before blocking the sections with a serum-free
blocking reagent (DAKO, UK) for 20 minutes. Using the optimal
dilution, the pZIP7 antibody incubation was carried out in a
humidity chamber for an hour at room temperature for the cell
pellets, whereas the tissue samples were incubated overnight at
23 1C. The slides were then washed twice with PBS/Tween
0.02% and probed with secondary antibody (Mouse Envision
labelled polymer-HPR #K4001, DAKO) for up to an hour followed by
another two washes with TBS/Tween 0.05%. The protein of interest
was then visualised using aDAB (30-30-diamobenzidine) chromogen-
substrate solution (DAKO). Counterstaining was performed with
methyl green 0.05% (aq.). The slides were then coverslipped using
DPX Mountant and visualised on an Olympus BH-2 microscope.
After determining a representative field for assessment, the pZIP7
immunostaining of the specimens was evaluated by consensus of
two personnel, recording percentage positivity according to staining
intensity category (i.e. 1, 2 and 3 corresponding to negative,
weak, intermediate and strong staining, respectively). The HScore
was then calculated as previously described using these data for
each specimen.35
Fluorescence-activated cell sorting (FACS analysis)
Zinc was measured using the cell permeant zinc-fluorescent dye
Fluozin-3AM (Invitrogen) using a BD FACSVerse Flow Cyto-
meter. Cells, 70–80% confluent on 35 mm dishes, were trypsinised
and incubated at 37 1C with 5 mM fluozin-3 for 30minutes, followed
by a 30minute incubation in freshmediumwith no Fluozin-3. FACS
results were analysed using FlowJo software.
Kaplan–Meier plotter analysis
ZIP7 gene expression data in relation to breast cancer survival
was assessed using publicly available online Kaplan–Meier
analysis (www.kmplot.com).36 Kaplan–Meier plots were generated
using Affymetrix microarray expression of ZIP7 mRNA (ID:
202667_s_at) in tumour samples from breast cancer patients that
were restricted to oestrogen receptor positive breast cancers treated
with tamoxifen only (n = 740) or with any endocrine treatment or
chemotherapy (n = 2061).
Statistical analysis
For the in vitro studies, statistical analysis was performed using
analysis of variance (ANOVA) with Dunnet post hoc. The diﬀerence
was considered significant when po 0.05. Data were plotted with
standard error of the mean (SEM) from at least n = 3/4
experiments. Statistical analysis of the pZIP7 HScores for the
clinical sample series was evaluated using SPSS non-parametric
statistical analyses. Spearman’s correlation test examined the
relationship between pZIP7 HScore and various biomarkers
or signalling pathway elements that had previously been eval-
uated using either immunostaining or PCR in the series.37
Mann-Whitney analysis was also performed to analyse pZIP7
level according to available clinicopathological parameters,
notably tumour size, tumour grade, menopausal status or
patient age. Statistical analysis was carried out using IBM SPSS
or GraphPad software.
C Results and discussion
Expression and activity of ZIP7 in tamoxifen and Faslodexs
resistance
Having previously seen an increase in ZIP7 expression and a
role for its signalling in TamR cells31 we were keen to explore
whether there was also a potential role for ZIP7 in further models
of anti-hormone resistance. In order to examine whether changes
in zinc signalling could be of more general importance in anti-
hormone resistance, we thus first examined the protein expres-
sion levels of zinc transporter ZIP7 which is responsible for the
release of zinc from intracellular stores. Using western blotting
analysis, we compared the protein levels of ZIP7 in the four cell
models of anti-hormone resistant breast cancer that had emerged
by up to 3 years in vitro, mimicking clinical development of this
disease state in many ER+ patients.21 These cell models aim to
represent acquired resistance to shorter (TamR, FasR) and longer
term (TamRL, FasRL) tamoxifen and Faslodexs treatment to
better reflect adjuvant endocrine (antioestrogen) treatment used
in breast cancer patients. A significant increase in total ZIP7
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protein expression was detected in both the TamR (p o 0.001)
and FasRL cells (po 0.05) compared to MCF-7 cells (Fig. 1A). More
modest increases were seen in the long-term TAMRL cells, which
was slightly decreased compared with the shorter time of tamoxifen
resistance. Data from the KM plotter tool showed that increased
ZIP7 at the mRNA level is significantly associated with a shorter
relapse-free survival (Fig. 1B) in ER-positive breast cancers, an
association that is largely retained within the cohort of these
patients treated with tamoxifen. These data fit with the results
obtained with Western blotting, showing that a significant
increase in total ZIP7 expression (SLC39A7) is also a feature
typical of anti-hormone resistant breast cancer cells that appears
particularly prominent for tamoxifen but also shows some
increases in cells that have developed resistance to the further
antioestrogen Faslodexs (Fig. 1A).
Most importantly, using our pS275S276ZIP7 antibody we next
revealed there was a significant four-fold increase in activated
ZIP7 in the TamR cell line (po 0.001) compared to MCF-7 cells
(Fig. 2A). Moreover, there was a significant increase (po 0.05) in
pZIP7 in the long-term resistance model of TamR (TamRL),
although with less amplitude, confirming the importance of
ZIP7 signalling in driving tamoxifen resistance. While the
Faslodexs-resistant cell line (FasR) showed no increase in
activated ZIP7 compared to MCF-7 cells, interestingly there was a
detectable increase in the level of pZIP7 as resistance pro-
gressed (FasRL) although this was more modest than seen with
Fig. 1 ZIP7 protein level is significantly increased in TamR and FasRL cells. (A) Immunoblotting of anti-hormone (tamoxifen or Faslodexs) resistant cell
lines probed with total ZIP7 antibody and compared to MCF-7 cells. Statistical analysis was performed on densitometric data normalised to b-actin
showing the mean values of n = 4  SEM with *** = po 0.001 and * = po 0.05 versus responsive MCF-7 cells. (B) KM plotter (www.kmplot.com) derived
survival plot showing patients with higher SLC39A7 mRNA expression had a shortened relapse free survival in both the tamoxifen treated ER+ (left graph;
n = 740) and whole ER+ breast cancer patient cohorts treated why any endocrine treatment or chemotherapy (right graph, n = 2061).
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Fig. 2 ZIP7 is significantly activated in TamR and TamRL cells. (A) Immunoblotting of anti-hormone (tamoxifen or Faslodexs) resistant cell lines probed with pZIP7
antibody and compared toMCF-7 cells. Statistical analysis was performed on densitometric data normalised to b-actin showing themean values of n=4 SEMwith
*** = po 0.001 and * = po 0.05 versus responsive MCF-7 cells. (B) Immunofluorescence of anti-hormone resistant cell lines probed for pZIP7 and compared to
MCF-7 cells. Cells were seeded on coverslips, fixedwith 3.7% formaldehyde and stained for pZIP7 antibody (red) along with DAPI (blue). Pictures are representative of
multiple assessments of each cell line model (n = 3) imaged with a 63 oil immersion lens using a Leica Microscope. While staining is substantial in most cells for
tamoxifen resistance, the arrows represent both highly pZIP7 positive (green) and lower positive (yellow) cells in the FasRL line. Scale bar: 10 mm.
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tamoxifen (Fig. 2A). These results in total suggested that levels
of phosphorylated ZIP7 may be a valuable marker of anti-hormone
resistance, particularly for tamoxifen, as there was evidence of
active ZIP7-mediated zinc signalling in these cell lines.
Assessing zinc signalling mechanisms in anti-hormone-
resistant breast cancer cells
Having demonstrated a significant increase in ZIP7 activation
in the TamR cells using Western blotting, we next wanted to
examine whether this represented amoderate increase of activated
ZIP7 in all cells or a large increase in a sub-population of the cells.
Using fluorescent microscopy, we compared the staining for pZIP7
in the diﬀerent cell lines using immunofluorescence. We observed
that 80–100% of TamR and TamRL cells stained positively for
pZIP7 (Fig. 2B) consistent with a location on the endoplasmic
reticulum membrane as demonstrated in a previous study.15 We
also observed much stronger staining in a proportion of the TamR
cells, in accordance with the Western blotting showing particularly
prominent ZIP7 activation in this model. In contrast, the FasR cells
had a much lower percentage of pZIP7 positive cells that was very
similar to the 10–20% positivity observed in the antihormone
responsive MCF-7 cells. Interestingly, there were patches of FasRL
cells that were more highly positive for pZIP7 surrounded by areas
that were relatively pZIP7 negative (Fig. 2B, coloured arrows). This
more obvious increase in the FasRL compared with FasR cells
again reflected the Western blotting findings for pZIP7.
We have previously demonstrated that one of the major
downstream targets of ZIP7-mediated zinc release17 is activation
of AKT on residue S473, so we next used Western blotting to
investigate whether activation of AKT was also observed in the
cell models that exhibited higher pZIP7. Normalisation of
phospho-AKT to the level of total AKT showed that the activation
of AKTwas considerably increased in TamR cells compared to the
MCF-7 cells (p o 0.05) (Fig. 3A) which agreed with our previous
data examining AKT signalling8 and was also consistent with the
suggested role for zinc signalling in these cells. Interestingly,
the longer-term variant of the TamR cells (TamRL) had an
even greater increase in AKT activation ( p o 0.01), suggesting
further potential changes in zinc signalling with progression
of tamoxifen resistance. While the Faslodexs resistant cell line
(FasR) showed no increase in activated AKT, again there was a
non-significant increase as resistance progressed in the FasRL
cell line which was consistent with a potential change in zinc
signalling in these cells (Fig. 3A). However, the same was not
consistently observed with activation of MAPK in the MCF7-
derived TamR line: while pMAPK was induced in some repli-
cates, these cells showed no overall robust significant increase
in MAPK activity compared to the MCF-7 cells, while the FasR
cells showed a significant decrease (po 0.05) (Fig. 3B). Further-
more, these levels did not significantly change in the long-term
FasRL and TamRL resistant models compared with their earlier
resistant counterparts.
Intracellular zinc in anti-hormone resistant cell lines
Having demonstrated changes in ZIP7 and especially pZIP7
in these anti-hormone resistant cell lines we next assessed
whether this corresponded to any measurable change in intra-
cellular available zinc content. Cells loaded with the zinc-
fluorescent dye Fluozin-3 had fluorescence assessed by FACS
analysis and demonstrated an increased intracellular available
zinc in TamR cells (p o 0.05) (Fig. 3C) which was consistent
with that we had observed previously.8 Interestingly, the avail-
able zinc decreased somewhat from TamR cells to TamRL cells,
consistent with the observed decrease in activated ZIP7 in the
longer-term TamRL cells (Fig. 2B). Additionally, the FasR cells
had significantly increased zinc levels (p o 0.05), similar to
those seen for TamR cells (Fig. 3C) which also decreased with
longer time of resistance. This interesting result seemed in
conflict with the pZIP7 data but highlighted that deregulated
zinc signalling may be a feature that is typical of anti-hormone
resistant cells. One well described eﬀect of ZIP7-mediated zinc
release from stores is to inhibit multiple tyrosine phosphatases.18
This allows prolonged activation of tyrosine kinases such as EGFR
and IGF1-R which are known to be responsible for driving the
growth of TamR cells.29 One major target of intracellular zinc is
PTP1B,38 a key phosphatase that dephosphorylates EGFR and
IGF1-R, and has been shown to be inhibited by zinc at physio-
logically relevant concentrations such as picomolar.39
Assessing ZIP7 activity in anti-hormone resistant cell lines
using immunostaining
We developed an immunohistochemical assay for our pZIP7
antibody (optimised using heat-mediated antigen retrieval) as
we wished to test paraﬃn-embedded clinical breast cancer
samples. We initially tested this method on cell pellets of our
anti-hormone resistant cells to monitor if there was consistency
with our Western blotting findings. The investigation on cell
pellets of the five cell lines (Fig. 4A) revealed a strong staining
for pZIP7 in the TamR cell line compared with MCF7, with all
cells staining positively and some showing 3+ intensity stain-
ing, consistent with the TamR cells utilising zinc signalling
pathways. Furthermore, the TamRL cells were also all positive
for pZIP7 but the staining was not as strong as that seen for the
TamR, again consistent with activation of zinc signalling at a
lesser level than TamR as seen from the Western blotting and
fluorescence studies. In contrast, the FasR cells showed more
heterogeneous staining with a less prominent increase compared
with the MCF-7 cells than seen for the tamoxifen resistant lines.
Interestingly, the FasRL cells had some more positive cells for
pZIP7 than the FasR cells, agreeing with theWestern blotting and
fluorescence observations (Fig. 2A and B). HScore evaluation of
the cell pellet staining confirmed these results with TamR cells
showing the highest pZIP7 HScore, confirming that this cell line
has active utilisation of ZIP7-mediated zinc signalling (Table 1)
and corroborating all previous data.
Assessing ZIP7 activity in clinical breast cancer samples using
immunostaining
In order to explore whether ZIP7 was also active in breast cancer
patients and following on from the staining analysis of the cell
pellets, we evaluated the pZIP7 antibody immunohistochemically
in a clinical series of paraﬃn-embedded breast cancer sections
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obtained from Nottingham City Hospital. This series comprised
samples from 93 primary breast cancer patients. Using the assay
optimised with heat-mediated antigen retrieval, there was pZIP7
staining in all the tumour epithelial cells in the cancer tissues,
demonstrating a widespread positivity to pZIP7 spanning a
range of positive staining scores (Fig. 4B). pZIP7 staining was
consistent with the protein location on the endoplasmic reticulum
membrane. Although some of the cancer samples had lower levels of
Fig. 3 Activated ZIP7 increases intracellular zinc and activates AKT in anti-hormone resistance. Western blot comparing Faslodexs and tamoxifen
anti-hormone resistant cell lines to MCF-7 cells probing for pS473AKT and total AKT (A) and pMAPK and total MAPK (B) on the same gel that had been cut
horizontally thus making the same GAPDH bands appropriate for both parts. Statistical analysis was performed on densitometric data normalised to the
total level of total AKT or MAPK showing the mean values of n = 4  SEM with ** = po 0.01 and * = po 0.05 versus responsive MCF-7 cells. The level of
GAPDH is also shown. Zinc content of cells was imaged using the fluorescent zinc indicator Fluozin-3AM and the total fluorescence was documented
using FACS analysis (C). Example plots are shown, with the graphical data showing mean values of n = 3 SEM with * = p o 0.05.
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pZIP7 staining, there was still evidence of staining in virtually all
cancer tissue (Fig. 4B), with an HScore of 0 in only one patient. The
range of positivity was up to anHScore of 250, with amedianHScore
for pZIP7 staining in the series of 117. Interestingly, pZIP7 staining
was only very low in tumour associated normal tissue (Fig. 4B),
contrasting the widespread staining of pZIP7 in the breast cancers.
Fig. 4 Immunohistochemical analysis of pZIP7 in breast cancer models and clinical samples. Formalin-fixed, paraﬃn-embedded cell pellet sections of
Faslodexs and tamoxifen anti-hormone resistant cell lines and the responsive MCF-7 cells were immunostained with pZIP7 antibody using DAB (3 0-30-
diaminobenzidine) chromogen, with methyl green counterstaining for the nuclei (A). Magnification: 40. Scale bar: 25 mm. Immunostaining for pZIP7 in
breast cancer sections from a clinical primary breast cancer series using the pZIP7 antibody (B). Samples are representative of high, moderate and low
staining of pZIP7 in the series (a–c), all of which was greater than that seen in the tumour associated normal breast tissue also on the sections (d). pZIP7
was visualised using DAB chromogen staining, with methyl green counterstaining for the nuclei. Magnification: 40. Scale bar: 25 mm.
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This clinical series had previously been assessed in some
samples at the protein, phospho-protein or mRNA level for a
variety of signalling parameters known to be relevant to endo-
crine resistance biology. While there were no outcome data
associated with these samples it was possible to examine the
levels of pZIP7 versus key clinicopathological endpoints that
were available for many patients, notably patient age, meno-
pausal status, tumour size, tumour grade, tumour stage and
proliferation (Tables 2 and 3). Of these clinicopathological
features, the only significant parameter associated with pZIP7
level was tumour grade (Table 2) where the level of pZIP7 was
significantly enriched in the higher-grade tumours (P = 0.046).
There was also a positive relationship between MAPK activity
(pMAPK) and pZIP7 (p = 0.019), confirming our recent data17
that pMAPK was a downstream target of pZIP7.17 There was
also a weak trend with PI3K expression, a signalling element
known to impact on AKT signalling (p = 0.092). Furthermore,
there was a modest positive correlation of pZIP7 in the series
with expression of the tyrosine kinase receptor ErbB2 ( p =
0.028) (Table 3). The analysis also showed a significant indirect
correlation between pZIP7 and the progesterone receptor (PR)
(p = 0.036) although no significant correlation of pZIP7 was seen
with the oestrogen receptor (ER) in either ER+ or ER disease. Both
ErbB2 and pMAPK, low PR, and high tumour grade are all known to
be features associated with endocrine resistance and disease pro-
gression in breast cancer,17,28 suggesting that higher levels of pZIP7
may be associated with resistant patients. Additionally, we noticed a
significant positive relationship between CD71 (transferrin receptor)
and pZIP7 levels (p = 0.017). The transferrin receptor can transport
zinc into cells in addition to its transport of iron40,41 and upregula-
tion of the transferrin receptor may partially explain the increased
intracellular available zinc observed in anti-hormone resistant cell
models. Higher levels of the transferrin receptor have also been
linked to tamoxifen resistance.42 Moreover, the analysis revealed a
significant correlation between the proto-oncogene c-Fos and pZIP7
(p = 0.007). The proto-oncogene c-Fos has again previously being
associated with tamoxifen resistance.43
The immunostaining observations in total suggested that
pZIP7 might (with further study) be relevant as a novel biomar-
ker for the diagnosis of breast cancer. Moreover, it will now be
interesting to expand this study further to assess pZIP7 levels in
breast cancer samples that have anti-hormone treatment data
associated with them to evaluate if elevated pZIP7 relates to
endocrine resistance.
Table 1 HScore values of cell pellets. The table indicates the HScore for
the pellet corresponding to each diﬀerent resistant cell line in comparison
to MCF-7 cells
Cell line HScore
MCF-7 95
FasR 115
FasRL 160
TamR 220
TamRL 175
Table 2 Mann–Whitney analysis examining pZIP7 in relation to clinicopathological parameters. The analysis of this data used the clinicopathological
parameters available on the SPSS database
Clinicopathological parameters p Value
Number
of patients Comment
Menopausal status p = 0.522 n = 82 Non-significant
Tumour grade (1/2 low-moderate vs. 3 high grade) p = 0.046 n = 91 Significant (pZIP7 levels higher
in grade 3 vs. 1/2)
Tumour stage (stage 1 = lymph node negative disease vs. 2/3 = lymph
node positive disease)
p = 0.331 n = 73 Non-significant
Table 3 Spearman’s correlation analysis between pZIP7 and diﬀerent endocrine markers. The analysis used the biomarker data available on the SPSS
database
Molecule Test Correlation p and R values Number Comment
Steroid hormone receptors
ER Protein No association p = 0.809, R = 0.025 n = 92 Non-significant
PR Protein Indirect p = 0.036, R = 0.234 n = 81 Significant
Growth factor receptors
ErbB2 mRNA Direct p = 0.028, R = 0.344 n = 41 Significant
EGFR mRNA No association p = 0.488, R = 0.122 n = 41 Non-significant
CD71/transferrin receptor Protein Direct p = 0.015, R = 0.252 n = 93 Significant
Transcription factors and other intracellular kinases
pMAPK Phospho-protein Direct p = 0.019, R = 0.244 n = 93 Significant
Fos Protein Direct p = 0.007, R = 0.280 n = 92 Significant
PI3K mRNA Direct p = 0.092, R = 0.103 n = 45 Weak association
Clinicopathological parameters
Age Protein p = 0.460, R = 0.079 n = 89 Non-significant
Tumour size Protein p = 0.139, R = 0.170 n = 77 Non-significant
Proliferation (Ki67) Protein p = 0.383, R = 0.093 n = 89 Non-significant
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D Conclusions
Despite the importance and requirement of zinc for human
health, which has been known for the last 60 years,44 relatively
little is known about the role of zinc in disease. The involvement
of zinc in several pathologies is an important emerging area and
now includes many cancers such as prostate cancer,45,46 liver
and pancreatic cancers,47–49 lung cancer,50 breast cancer51,52 as
well as providing promise for new cancer treatments.
The present study is focused on ZIP7, a member of the LIV-1
subfamily of ZIP transporters which is known to be relevant in
many poor prognostic cancer states.9 Recently, knockdown of
SLC39A7 has been shown to inhibit cell growth and induce
apoptosis in human colorectal cancer cells.53 ZIP7 has also
been demonstrated to drive a tamoxifen-resistant breast cancer
model (TamR),8 where such resistance is an increasing problem
in the breast cancer clinic.28 ZIP7 activates downstream tyrosine
kinase pathways such as EGFR, IGF-1R and Src in such cells8 as
a direct result of its ability to inhibit tyrosine phosphatases and
activate MAPK, PI3K and mTOR pathways,17 which are consistent
with activation of these kinases, known to drive the growth of
tamoxifen-resistant breast cancer.8
Here we have demonstrated a significant increase in pZIP7
in TamR cells compared to MCF-7 cells which was a more
pronounced increase than that detected using the total ZIP7
antibody. Increased ZIP7 activation was also seen with more
prolonged exposure to tamoxifen in the longer-term model,
suggesting some importance for activation of zinc signalling
pathways in resistance irrespective of the duration of tamoxifen
treatment. Interestingly, we also discovered that in contrast to
MCF-7 cells almost all of the TamR cells were positive for pZIP7
suggesting they were actively using zinc signalling pathways
controlled by ZIP7-mediated zinc release from stores. These
results were confirmed by immunohistochemistry on cell pellets
of the same resistant cell lines (an observation that also helped
validate the antibody for use on paraﬃn-embedded material).
Furthermore, this result was also evident in the breast cancer
tissue samples, where pZIP7 was expressed in virtually all
tumours and at elevated levels in those with features that were
associated with resistance and progression, suggesting a
potential clinical relevance for pZIP7 as a biomarker of cancer
and also potentially of tamoxifen failure. This elevation of
activated ZIP7 was further confirmed by the increased intracellular
available zinc levels observed which was consistent with our previous
data showing increased zinc in TamR cells8 in conjunction with a
raised expression of ZIP7.31 We also showed how the increased level
of activated ZIP7 is consistent with activation of AKT in the TamR
cells, a major downstream target of ZIP7-mediated zinc signalling17
and a molecule with a known role in cancer progression.33
These findings are supportive of our hypothesis that a higher
zinc signalling capability may lead to the development of resistance
in ER+ breast cancer patients treated with tamoxifen. It is
fascinating to see the full extent of cell positivity for pZIP7 in
the TamR cells which is irrespective of duration of exposure to
the drug, making pZIP7 a prominent characteristic that appears
typical of tamoxifen-resistance.
Although there was no obvious increase of pZIP7 in FasR
cells compared to MCF-7 cells, there was a modest increase of
pZIP7 in the FasRL line, suggesting a potential value for pZIP7 as
a biomarker relating to resistance emerging after more prolonged
Faslodexs treatment. The modest increase of activated ZIP7 in
the long-term FasRL model could have been a result of the
increased protein level of ZIP7 in this cell line as confirmed by
measurement with the total ZIP7 antibody. Further to our studies
previously carried out only in TamR cells, we also demonstrated
that the FasR cells have a significantly increased level of available
zinc, as noted for TamR cells.8 Surprisingly this increased level of
available zinc did not reflect the activation of ZIP7 which was only
higher in the long term FasRL cells. Moreover, the models of
Faslodexs resistant breast cancer did not show the same
increased activation of downstream pathways which have been
directly linked to ZIP7 activation, such as AKT (and to a lesser
degree MAPK),17 in the TamR cells. Indeed, this study revealed
that FasR cells, both shorter and longer-term, had a significant
decrease of MAPK signalling. This result could be reflective of the
fact that these Faslodexs resistant models are oestrogen receptor
negative,54 due to the action of Faslodexs exposure which
induces the loss of the ER protein,23 contrasting the maintenance
of this receptor in the TamR line.55 There is already an established
cross-talk mechanism between the oestrogen receptor and MAPK
pathway activation in the TamR cells.56 A recent investigation of
clinical samples from patients treated with Faslodexs confirmed a
significant decrease of active MAPK signalling.57 While the present
study provided novel information regarding use of zinc signalling in
FasR cells, it also highlighted that Faslodexs resistance may be
driven by zinc signallingmechanisms other than ZIP7, which are yet
to be fully understood. Nevertheless, the increase of intracellular
available zinc in both the FasR cells and tamoxifen resistant
lines has confirmed that an increase of intracellular zinc is a
characteristic likely to be typical of endocrine resistance.
While considerable further study is needed, the investigation
of pZIP7 using immunostaining on clinical breast cancer
samples here is certainly suggestive of the potential for using
pZIP7 as a novel biomarker to help diagnose breast cancer.
pZIP7 staining positivity was abundant in almost all patient
samples from the clinical series used in this investigation, in
contrast to the tumour associated normal breast tissue which
stained poorly for pZIP7. ZIP7 activation was abundant in the
clinical samples irrespective of their ER status, suggesting that it
could be a useful biomarker of breast cancer that is not
restricted to ER-positive disease. More interestingly, analysis
of clinicopathological features revealed an association between
increased activated ZIP7 and breast cancer patients with the
poor prognostic feature of high grade. Furthermore, our study
has confirmed the previous mechanistic links reported between
pZIP7 and active MAPK signalling.17 There was also a trend with
PI3K expression, confirming previous associations of pZIP7 with
activation of PI3K/AKT signalling.17 Moreover, pZIP7 levels
associated with transferrin receptor CD71 expression in the
breast cancer samples, which is known to transport zinc as well
as iron41 and so may also contribute to the increased cytoplasmic
zinc seen in endocrine resistant cells since this receptor is also
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expressed in such models.42 Although there is no data concerning
iron levels in endocrine resistant breast cancer, it will be important
to consider this for future studies, especially in light of the
important role of both iron and zinc in cell growth.58,59 Inter-
estingly, the transferrin receptor has already been associated
with an increase in proliferation which is a hallmark of
aggressive cancer and in particular breast cancers that have
developed resistance to tamoxifen,42 suggesting this association
may in part be due to transferrin receptor influxing zinc into
cells. Delivery of zinc via transferrin receptor and by ZIP7
activation may thus synergistically promote a more aggressive,
endocrine resistant phenotype of breast cancer. In keeping with
this, pZIP7 staining in the breast cancer series here was also
significantly associated with high tumour grade, as well as with
pMAPK which can be a feature of endocrine resistant tumours.60
There was also an indirect association between pZIP7 and the
progesterone receptor (PR), highlighting the possibility that pZIP7
is enriched in tumours that are PR negative and often tumours
that are more likely to be endocrine resistant as the progesterone
receptor is a known marker of hormone responsiveness.61 More-
over, tumours that are PR negative have been associated with a
higher risk of mortality in comparison to PR positive tumours.62
Our study has additionally revealed a significant correlation
between pZIP7 and the ErbB2 receptor. It is well established from
previous studies that tumours which overexpress the ErbB2
(HER2) receptor are more likely to be endocrine resistant due to
the increased activation of growth factor pathways.63 Another
important discovery here was the association of pZIP7 to the
proto-oncogene c-Fos. This proto-oncogene is known to be asso-
ciated with zinc status, as experiments have shown that human
bronchial cells supplemented with zinc exhibit a two-fold increase
of c-Fos mRNA in comparison to cells with a basal level of zinc.64
Therefore, the increased level of zinc (discovered here in endocrine
resistant cells) as a direct result of ZIP7 activation could be one
mechanism promoting c-Fos in breast cancer. This adds further
evidence to our hypothesis that the zinc/pZIP7 mechanism is a key
driver of disease progression since previous associations have been
reported between c-Fos and endocrine resistance.43
In total, our experimental and clinical profiling evidence
indicate that activation of ZIP7 may be associated with poorer
prognosis in breast cancer and with the risk of developing
endocrine resistance. Future studies of clinical samples are
needed to explore pZIP7 staining versus endocrine outcome.
Nevertheless, it was perhaps also reassuring that there was some
association between shorter time to relapse in tamoxifen treated
patients and ZIP7, albeit at the mRNA level, using KM Plotter.
The discovery here that pZIP7 might have potential as a bio-
marker of anti-hormone resistant breast cancer also paves the
way for further investigations of targeting this new mechanism
to tackle the development of resistance. Knowing that ZIP7
activation on residues S275 and S276 is induced by CK2
phosphorylation,16 one approach might be to target ZIP7 signal-
ling using CK2 inhibitors. A CK2 inhibitor (CX-4945, Silmitasertib),
which is currently under investigation for its possible use on drug
resistant cells,65 has shown promising preliminary results
(Taylor et al., unpublished) suggesting it can slow the growth
of TamR cells. Moreover, this CK2 inhibitor is able to be inter-
nalised in resistant cells with a subsequent ability to induce cell
death.65 CK2 is a protein kinase whose role in tumorigenesis is
well established66 and for this reason the drug CX-4945 is currently
in further cancer clinical trials, including in combination with
chemotherapy for its use against cholangiocarcinoma (Clinical-
Trials.Gov Identifier: NCT02128282) and also for the treatment of
multiple myeloma (ClinicalTrials.Gov Identifier: NCT01199718).
This drug also has potential to block cell proliferation in haemato-
logical tumours and in other cancer cell lines in vitro.65,67 The use of
the CK2 inhibitor CX-4945 on tamoxifen-resistant cells will
require further investigation, but the promising preliminary
data in TamR cells suggests study in endocrine resistant disease
may also be warranted.
In conclusion, we have demonstrated the potential of pZIP7
as a biomarker for breast cancer, with our cell model and
clinical breast cancer findings indicating particular promise in
the context of patients developing resistance to anti-hormonal
agents, notably tamoxifen. Furthermore, since ZIP7 is activated
by protein kinase CK2, our data is also suggestive that using a
CK2 inhibitor, such as CX-4945, in conjunction with anti-
hormones is worthy of exploration in the context of preventing
the onset and progression of resistant disease states.
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